Cargando…

Detection of SARS-CoV-2 antibodies after confirmed Omicron BA.1 and presumed BA.4/5 infections using Abbott ARCHITECT and Panbio assays

BACKGROUND: Commercial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests were developed before variants with spike protein mutations emerged, leading to concerns that these tests have reduced sensitivity for detecting antibody responses in individuals infected with Omicron...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boler, Michael, Anderson, Mark, Rodgers, Mary, Parumoottil, Jessica, Olivo, Ana, Harris, Barbara, Stec, Michael, Gosha, Amy, Behun, Dylan, Holzmayer, Vera, Anderson, Abby, Greenholt, Ella, Fortney, Tiffany, Almaraz, Eduardo, Cloherty, Gavin, Landay, Alan, Moy, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Coronavirus (COVID-19) Collection
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174724/ https://www.ncbi.nlm.nih.gov/pubmed/37234563 http://dx.doi.org/10.1016/j.ijregi.2023.04.014

Ejemplares similares

Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals
por: Kuzel, Timothy G, et al.
Publicado: (2023)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay
por: Batra, Rahul, et al.
Publicado: (2020)

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2
por: Hu, Bingjie, et al.
Publicado: (2022)

Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai
por: Wu, Qianhui, et al.
Publicado: (2023)

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022
por: Chen, Xinhua, et al.
Publicado: (2022)

Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections
por: Tso, Winnie W.Y., et al.
Publicado: (2022)

Effectiveness of first and second boost COVID-19 vaccination in healthy adults during BA.5.2/BF.7 surge in China
por: Zhang, Yongchang, et al.
Publicado: (2023)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
por: Rissmann, Melanie, et al.
Publicado: (2022)

Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections
por: Saade, Carla, et al.
Publicado: (2022)

Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain)
por: Ciuffreda, Laura, et al.
Publicado: (2023)

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination(1)
por: Wang, Hongyu, et al.
Publicado: (2023)

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study
por: Zhang, Xiaqing, et al.
Publicado: (2023)

The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees
por: Dapporto, Francesca, et al.
Publicado: (2022)

Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
por: Liu, Shuo, et al.
Publicado: (2023)

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2022)

SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine
por: Anderson, Mark, et al.
Publicado: (2021)

Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-19
por: Stokes, William, et al.
Publicado: (2021)

Verification of Abbott 25-OH-vitamin D assay on the architect system
por: Hutchinson, Katrina, et al.
Publicado: (2017)

Performance of the Abbott Architect Immuno-Chemiluminometric NT-proBNP Assay
por: Lau, Chin-Shern, et al.
Publicado: (2022)

Evaluation of the Abbott Panbio(™) COVID-19 antigen detection rapid diagnostic test among healthcare workers in elderly care
por: Eikelenboom-Boskamp, Andrea, et al.
Publicado: (2023)

Sex difference in the discordance between Abbott Architect and EuroImmun serological assays
por: Hartsell, Joel D., et al.
Publicado: (2023)

Performance evaluation of Roche and Abbott Panbio multiplex SARS-CoV-2 and influenza A/B rapid antigen tests
por: Batty, Mitchell, et al.
Publicado: (2023)

Expanding access to SARS-CoV-2 IgG and IgM serologic testing using fingerstick whole blood, plasma, and rapid lateral flow assays
por: Anderson, Mark, et al.
Publicado: (2021)

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
por: Zou, Jing, et al.
Publicado: (2023)

Berbamine suppresses intestinal SARS-CoV-2 infection via a BNIP3-dependent autophagy blockade
por: Cloherty, Alexandra P. M., et al.
Publicado: (2023)

Evaluation of the Abbott Panbio(TM) COVID-19 Ag rapid antigen test for the detection of SARS-CoV-2 in asymptomatic Canadians
por: Shaw, Julie L V, et al.
Publicado: (2021)

To BaP or not to BaP? That is the question.
por: Goldstein, L S
Publicado: (2001)

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1
por: Hu, Yanping, et al.
Publicado: (2023)

Assessment of Abbott Architect 25-OH vitamin D assay in different levels of vitamin D
por: Avci, Esin, et al.
Publicado: (2020)

Kinetics and performance of the Abbott architect SARS-CoV-2 IgG antibody assay
por: Hamilton, Fergus, et al.
Publicado: (2020)

Multi‐center evaluation of the highly sensitive Abbott ARCHITECT and Alinity thyroglobulin chemiluminescent microparticle immunoassay
por: Evans, Carol, et al.
Publicado: (2022)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients
por: Fu, Jia, et al.
Publicado: (2022)

Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests
por: Rodgers, Mary A, et al.
Publicado: (2022)

Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
por: Torres, Carolina, et al.
Publicado: (2023)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
por: Muik, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t81400p3it53ruq36nprc0j147